<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2018-17-2-5-10</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-708</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>МЕДИКО-СОЦИАЛЬНАЯ И КЛИНИЧЕСКАЯ ХАРАКТЕРИСТИКА КОГОРТЫ ПАЦИЕНТОВ С МЫШЕЧНО-НЕИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ</article-title><trans-title-group xml:lang="en"><trans-title>SOCIAL AND CLINICAL CHARACTERISTICS OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8784-8415</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каприн</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaprin</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, академик РАН, заслуженный врач РФ, генеральный директор ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия).</p><p>SPIN-код: 1759-8101</p><p>Author ID (Scopus): 6602709853</p></bio><bio xml:lang="en"><p>MD, Professor, Member of the Russian Academy of Sciences, Director of National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 6602709853</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0206-043X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аполихин</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Apolikhin</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, член-корр. РАН, директор НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия).</p><p>SPIN-код: 4617-3533</p><p>Author ID (Scopus): 683661</p></bio><bio xml:lang="en"><p>MD, Professor, Corresponding Member of the Russian Academy of Sciences, Director of Research Institute of Urology and Interventional Radiology affiliated to the National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 683661</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеев</surname><given-names>Б. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Alexeev</surname><given-names>B. Ya.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заместитель генерального директора по науке ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия)</p><p>SPIN-код: 4692-5705</p><p>Author ID (Scopus): 651796</p></bio><bio xml:lang="en"><p>MD, Professor, Deputy Director for Science, National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 651796</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рощин</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Roshchin</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, заведующий отделом НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия).</p><p>SPIN-код: 32793170.</p><p>Author ID (Scopus): 695562.</p></bio><bio xml:lang="en"><p>MD, PhD, Research Institute of Urology and Interventional Radiology affiliated to the National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 695562</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Качмазов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kachmazov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, заведующий отделением НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия)</p><p>SPIN-код: 3092-8047.</p><p>Author ID (Scopus): 793473.</p></bio><bio xml:lang="en"><p>MD, PhD, Research Institute of Urology and Interventional Radiology affiliated to the National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 793473</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8566-314X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перепечин</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Perepechin</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, старший научный сотрудник НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия)</p><p>SPIN-код: 6170-6832</p><p>Author ID (Scopus): 689150</p></bio><bio xml:lang="en"><p>MD, PhD, Senior Researcher, Research Institute of Urology and Interventional Radiology affiliated to the National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 689150</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Головащенко</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Golovashchenko</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, врач-онколог МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России (г. Москва, Россия)</p><p>SPIN-код: 8082-1075</p><p>Author ID (Scopus): 714890</p></bio><bio xml:lang="en"><p>MD, PhD, P.A. Gertsen Moscow Research Institute of Oncology affiliated to National Medical Research Center of Radiology (Moscow, Russia)</p><p>Author ID (Scopus): 714890.</p></bio><email xlink:type="simple">dz89031990702@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации, г. Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Radiology, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>07</day><month>05</month><year>2018</year></pub-date><volume>17</volume><issue>2</issue><fpage>5</fpage><lpage>10</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каприн А.Д., Аполихин О.И., Алексеев Б.Я., Рощин Д.А., Качмазов А.А., Перепечин Д.В., Головащенко М.П., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Каприн А.Д., Аполихин О.И., Алексеев Б.Я., Рощин Д.А., Качмазов А.А., Перепечин Д.В., Головащенко М.П.</copyright-holder><copyright-holder xml:lang="en">Kaprin A.D., Apolikhin O.I., Alexeev B.Y., Roshchin D.A., Kachmazov A.A., Perepechin D.V., Golovashchenko M.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/708">https://www.siboncoj.ru/jour/article/view/708</self-uri><abstract><p>Методом сплошного наблюдения был проведен ретроспективный анализ базы данных 581 медицинской карты стационарных больных пациентов с мышечно-неинвазивным раком мочевого пузыря. Из 581 больного, включенного в когорту исследования, 114 женщин и 467 мужчин: коэффициент преобладания мужчин в когорте составил 4,1 к 1. Среди мужской популяции доминирующая возрастная группа представлена лицами среднего возраста – 45,8 % всех обратившихся за медицинской помощью. На пожилых мужчин приходится 33,4 %, а доля мужчин моложе 44 лет составляет 16 % от всех заболевших. Среди женщин более половины – лица пожилого возраста (58,7 %), доля женщин среднего возраста равна 26,5 %, на лиц старческого возраста приходится 14,3 %. При сопоставлении возрастной структуры пациентов с их полом отмечается статистически значимый сдвиг в преобладании среди болеющих женщин лиц пожилого возраста. При этом доля болеющих женщин среднего возраста почти в два раза меньше соответствующей доли мужчин данной возрастной группы. Значимым отличием является также почти полное отсутствие среди больных женщин лиц молодого возраста. Подавляющее большинство пациентов, составивших когорту исследования, являются жителями Центрального федерального округа с преимущественным проживанием в г. Москве и Московской области. Как мужская, так и женская части когорты пациентов в большей степени подвержены негативному воздействию табакокурения (в настоящем и в анамнезе). Представители обоих полов с существенным, почти трехкратным преобладанием мужчин, отмечают периоды экспозиции химических канцерогенов, связанные с особенностями профессиональной деятельности. Также среди мужчин и женщин с долей в 3,2 и 1,9 % установлены факты наличия в анамнезе проведения лучевой терапии. При изучении локализации опухолевого узла установлено преимущественное поражение стенки органа, в два раза реже поражается дно пузыря, с частотой 13 и 9 % патологический процесс развивается в шейке и на верхушке органа. Мультицентрическая локализация опухоли встречается у 6 % пациентов когорты. В структуре глубины поражения мочевого пузыря опухолевым процессом доминирует Grade 1, установленная у 53 % пациентов. Более глубокое поражение, характеризующееся как Grade 2, 3, выявлено у 29 и 18 % пациентов соответственно. Установлено, что по изученным параметрам когорта воспроизводит основные закономерности и характеристики для данной категории пациентов.</p></abstract><trans-abstract xml:lang="en"><p>A retrospective analysis of medical records of 581 patients with non-muscle-invasive bladder cancer was carried out. Out of these patients, there were 467 men and 114 women, with a male-to-female ratio of 4:1. Among males, the highest incidence of non-muscle-invasive bladder cancer occurred in age range 45–59 year followed by age groups 60‑74 and 18‑44 years, representing 45.8 %, 33.4 %, and 16 %, respectively. For females, the highest incidence rate was observed in the 60 to 74 age group (58.7 %). Women aged 45‑59 and 75‑90 years represented 26.5 % and 14.3 %, respectively. The proportion of women aged 45‑49 years was almost half the proportion of men of this age group. Among female patients, there were very few women under 44 years. The vast majority of patients were residents of the Central Federal District with a primary residence in Moscow and the Moscow region. Both male and female patients were more susceptible to negative effects of smoking. Both male and female patients experienced occupational exposure to chemical carcinogens, with 3:1 male predominance. Men represented a higher proportion of those who received radiation therapy as compared to women (3.2 % versus 1.9 %). The bladder wall was the most frequent site of tumor location. The bladder fundus invasion occurred two times less frequently. The frequency of the bladder neck and apex invasion was 13 % and 9 %, respectively. Multicentric bladder cancer was observed in 6 % of the patients. Grade 1 cancer was the most common (53 %) followed by grade 2 and grade 3 (29 % and 18 %, respectively). According to results obtained, the studied cohort demonstrates the main social and clinical characteristics for patients with non-muscle-invasive bladder cancer.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мышечно-неинвазивный рак мочевого пузыря</kwd><kwd>структура</kwd><kwd>факторы риска</kwd><kwd>медико-социальная характеристика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-muscle-invasive bladder cancer</kwd><kwd>risk factors</kwd><kwd>medical-social characteristics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun; 27 (3): 289–93. doi: 10.1007/s00345 009 0383 3.</mixed-citation><mixed-citation xml:lang="en">Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun; 27 (3): 289–93. doi: 10.1007/s00345 009 0383 3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan; 63 (1): 11–30. doi: 10.3322/caac.21166.</mixed-citation><mixed-citation xml:lang="en">Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan; 63 (1): 11–30. doi: 10.3322/caac.21166.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fajkovic H., Halpern J.A., Cha E.K., Bahadori A., Chromecki T.F., Karakiewicz P.I., Breinl E., Merseburger A.S., Shariat S.F. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011 Aug; 29 (4): 457–63. doi: 10.1007/s00345 011 0709 9.</mixed-citation><mixed-citation xml:lang="en">Fajkovic H., Halpern J.A., Cha E.K., Bahadori A., Chromecki T.F., Karakiewicz P.I., Breinl E., Merseburger A.S., Shariat S.F. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011 Aug; 29 (4): 457–63. doi: 10.1007/s00345 011 0709 9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Abdollah F., Gandaglia G., Thuret R., Schmitges J., Tian Z., Jeldres C., Passoni N.M., Briganti A., Shariat S.F., Perrotte P., Montorsi F., Karakiewicz P.I., Sun M. Incidence, survival and mortality rates of stage speciﬁc bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013 Jun; 37 (3): 219–25. doi: 10.1016/j.canep.2013.02.002.</mixed-citation><mixed-citation xml:lang="en">Abdollah F., Gandaglia G., Thuret R., Schmitges J., Tian Z., Jeldres C., Passoni N.M., Briganti A., Shariat S.F., Perrotte P., Montorsi F., Karakiewicz P.I., Sun M. Incidence, survival and mortality rates of stage speciﬁc bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013 Jun; 37 (3): 219–25. doi: 10.1016/j.canep.2013.02.002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Boufﬁoux C., Denis L., Newling D.W., Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar; 49 (3): 466–5; discussion 475–7.</mixed-citation><mixed-citation xml:lang="en">Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Boufﬁoux C., Denis L., Newling D.W., Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar; 49 (3): 466–5; discussion 475–7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez-Gomez J., Madero R., Solsona E., Unda M., Martinez-Piñeiro L., Gonzalez M., Portillo J., Ojea A., Pertusa C., Rodriguez-Molina J., Camacho J.E., Rabadan M., Astobieta A., Montesinos M., Isorna S., Muntañola P., Gimeno A., Blas M., Martinez-Piñeiro J.A. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette Guerin: the CUETO scoring model. J Urol. 2009; 182 (5): 2195–203. doi: 10.1016/j.juro.2009.07.016.</mixed-citation><mixed-citation xml:lang="en">Fernandez-Gomez J., Madero R., Solsona E., Unda M., Martinez-Piñeiro L., Gonzalez M., Portillo J., Ojea A., Pertusa C., Rodriguez-Molina J., Camacho J.E., Rabadan M., Astobieta A., Montesinos M., Isorna S., Muntañola P., Gimeno A., Blas M., Martinez-Piñeiro J.A. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette Guerin: the CUETO scoring model. J Urol. 2009; 182 (5): 2195–203. doi: 10.1016/j.juro.2009.07.016.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein J.I., Amin M.B., Reuter V.R., Mostoﬁ F.K. The World Health Organization. International Society of Urological Pathology consensus classiﬁcation of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998 Dec; 22 (12): 1435–48.</mixed-citation><mixed-citation xml:lang="en">Epstein J.I., Amin M.B., Reuter V.R., Mostoﬁ F.K. The World Health Organization. International Society of Urological Pathology consensus classiﬁcation of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998 Dec; 22 (12): 1435–48.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Гланц С. Медико биологическая статистика. М., 1999. 467.</mixed-citation><mixed-citation xml:lang="en">Glantz S. Medico biological statistics. Moscow, 1999. 467. [in Russian]</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cárdenas-Turanzas M., Cooksley C., Pettaway C.A., Sabichi A., Grossman H.B., Elting L. Comparative outcomes of bladder cancer. Obstet. Gynecol. 2006; 108 (1): 169–175.</mixed-citation><mixed-citation xml:lang="en">Cárdenas-Turanzas M., Cooksley C., Pettaway C.A., Sabichi A., Grossman H.B., Elting L. Comparative outcomes of bladder cancer. Obstet. Gynecol. 2006; 108 (1): 169–175.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Lotan Y. Epidemiology and risk factors of urothe lial bladder cancer. Eur Urol. 2013; 63 (2): 234–241. doi: 10.1016/j. eururo.2012.07.033.</mixed-citation><mixed-citation xml:lang="en">Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Lotan Y. Epidemiology and risk factors of urothe  lial bladder cancer. Eur Urol. 2013; 63 (2): 234–241. doi: 10.1016/j. eururo.2012.07.033.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011 Aug 17; 306 (7): 737–45. doi: 10.1001/ jama.2011.1142.</mixed-citation><mixed-citation xml:lang="en">Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011 Aug 17; 306 (7): 737–45. doi: 10.1001/ jama.2011.1142.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., Boyle P. Tobacco smoking and cancer: a meta analysis. Int J Cancer. 2008 Jan 1; 122 (1): 155–64.</mixed-citation><mixed-citation xml:lang="en">Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., Boyle P. Tobacco smoking and cancer: a meta analysis. Int J Cancer. 2008 Jan 1; 122 (1): 155–64.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Harling M., Schablon A., Schedlbauer G., Dulon M., Nienhaus A. Bladder Cancer among hairdressers: a meta analysis. Occup Environ Med. 2010 May; 67(5): 351–8. doi: 10.1136/oem.2009.050195.</mixed-citation><mixed-citation xml:lang="en">Harling M., Schablon A., Schedlbauer G., Dulon M., Nienhaus A. Bladder Cancer among hairdressers: a meta analysis. Occup Environ Med. 2010 May; 67(5): 351–8. doi: 10.1136/oem.2009.050195.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Weistenhofer W., Blaszkewicz M., Bolt H.M., Golka K. N acetyl transferase 2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J Toxicol Environ Health A. 2008; 71 (13–14): 906–10. doi: 10.1080/15287390801988681.</mixed-citation><mixed-citation xml:lang="en">Weistenhofer W., Blaszkewicz M., Bolt H.M., Golka K. N acetyl  transferase 2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J Toxicol Environ Health A. 2008; 71 (13–14): 906–10. doi: 10.1080/15287390801988681.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zelefsky M.J., Housman D.M., Pei X., Alicikus Z., Magsanoc J.M., Dauer L.T., St Germain J., Yamada Y., Kollmeier M., Cox B., Zhang Z. Incidence of secondary cancer development after high dose intensity modulated radiotherapy and image guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83 (3): 953–9. doi: 10.1016/j.ijrobp.2011.08.034.</mixed-citation><mixed-citation xml:lang="en">Zelefsky M.J., Housman D.M., Pei X., Alicikus Z., Magsanoc J.M., Dauer L.T., St Germain J., Yamada Y., Kollmeier M., Cox B., Zhang Z. Incidence of secondary cancer development after high dose intensity modulated radiotherapy and image guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83 (3): 953–9. doi: 10.1016/j.ijrobp.2011.08.034.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nieder A.M., Porter M.P., Soloway M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008 Nov; 180 (5): 2005–9; discus sion 2009–10. doi: 10.1016/j.juro.2008.07.038.</mixed-citation><mixed-citation xml:lang="en">Nieder A.M., Porter M.P., Soloway M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008 Nov; 180 (5): 2005–9; discus  sion 2009–10. doi: 10.1016/j.juro.2008.07.038.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
